Core Laboratories N.V.
CLB · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $524 | $510 | $490 | $470 |
| % Growth | 2.8% | 4.1% | 4.1% | – |
| Cost of Goods Sold | $435 | $416 | $411 | $386 |
| Gross Profit | $88 | $94 | $79 | $84 |
| % Margin | 16.9% | 18.4% | 16.1% | 17.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $39 | $40 | $38 | $44 |
| SG&A Expenses | $39 | $39 | $38 | $44 |
| Sales & Mktg Exp. | $0 | -$1 | $0 | $0 |
| Other Operating Expenses | -$9 | $1 | -$1 | -$6 |
| Operating Expenses | $30 | $39 | $37 | $39 |
| Operating Income | $59 | $55 | $42 | $45 |
| % Margin | 11.2% | 10.7% | 8.5% | 9.6% |
| Other Income/Exp. Net | -$12 | -$13 | -$12 | -$9 |
| Pre-Tax Income | $46 | $41 | $30 | $36 |
| Tax Expense | $14 | $4 | $10 | $16 |
| Net Income | $31 | $37 | $19 | $20 |
| % Margin | 6% | 7.2% | 4% | 4.2% |
| EPS | 0.67 | 0.79 | 0.42 | 0.43 |
| % Growth | -15.2% | 88.1% | -2.3% | – |
| EPS Diluted | 0.66 | 0.77 | 0.42 | 0.42 |
| Weighted Avg Shares Out | 47 | 47 | 46 | 46 |
| Weighted Avg Shares Out Dil | 48 | 48 | 47 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $12 | $13 | $12 | $9 |
| Depreciation & Amortization | $15 | $16 | $17 | $19 |
| EBITDA | $73 | $70 | $59 | $64 |
| % Margin | 14% | 13.8% | 12% | 13.6% |